- Issuer ticker
-
IKT
- Reported as of
-
19 Oct 2026
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
4 source fields
- SEC form
-
4
- Accepted by SEC
-
21 Oct 2026, 16:10:04 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ David McIntyre, attorney-in-fact
Filing notes and source
Key filing fact
Scott M. Wasserman filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 21 Oct 2026.
Key facts
- This page summarizes Scott M. Wasserman's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Oct 2026, 16:10.
Change
- Previous filing in this sequence was filed on 16 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0002118767
Primary reporting owner
Wasserman Scott M.
- Relationship
-
Director
- Address
- 1000 N. WEST STREET, SUITE 1200, WILMINGTON
- Signature
- /s/ David McIntyre, attorney-in-fact
- Signature date
- 21 Oct 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +310,000
- Change %
- Price
-
$0.000000*
- Shares after
- 310,000
- Date
- 19 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 310,000
- Exercise price
- $1.64
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote